Replimune to resubmit twice-rejected drug for approval after FDA shakeup
CNBC
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC